Development

SRA737

SRA737 – A SELECTIVE CHK1 INHIBITOR

SRA737 is a potent, highly selective, orally bioavailable, small molecule inhibitor of Checkpoint kinase 1 (Chk1).

SRA737 is being investigated in two Phase 1/2 clinical trials in patients with advanced cancer:

  • SRA737-01 Phase 1/2 Monotherapy Trial
    For more information, visit ClinicalTrials.gov, identifier: NCT02797964
  • SRA737-02 Phase 1/2 Low Dose Gemcitabine Combination Trial
    For more information, visit ClinicalTrials.gov, identifier: NCT02797977